News FDA knocks back Biogen's high-dose Spinraza Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.
News Lilly names Houston as site for $6.5bn API facility Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.
News Manufacturing issues block FDA nod for Scholar Rock SMA drug Unresolved issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's SMA drug apitegromab.
News Roche's oral SERD comes good in 2nd-line breast cancer trial Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.
News Angelini taps Sovargen for epilepsy drug in $550m deal Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.
News BMS says it will set Cobenfy's UK price the same as the US Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.
Patients Making direct-to-patient work, with Matt Wadyka Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
